Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: Carson O. Ray, Jr. who wrote (243)	5/11/1999 5:24:00 PM
From: John Romeo	Respond to of 513

I have bought and sold Tcell since 1988 at times over $12-13 share.I am long this stock for 5 years at $4 3/8. In my opinion this company is a bag of crap. They spent years and tens of millions developing their proprietary Cd4 tcell test kit which was to drop the cost from hundreds of dollars per test to tens of dollars. They got approval and dropped the ball and sold zilch. They hired a company owned by an almost bankrupt Ivax to sell the kit and it failed miserably.They also developed a CD8 test kit which was never submitted for FDA approval. After tens of millions in investment and research they have nothing to show for these test kits. This is happening at a time when new major HIV drugs such as Protease Inhibitors, Nonnucleoside reverse transcriptase inhibitors,NNRTI's and nucleoside reverse transcriptase inhibitors are in great demand as they are used in the new lifesaving AIDS cocktails.Testing for Tcell levels are much higher now as they are used as one of two target data to determine what stage the disease is in a particular individual. Timing could not be better for this product,yet the company has dropped the ball and will not even discuss this utter failure and waste of millions of shareholders money. We are in a position now where emphasis is placed on treating different diseases.Organ rejection,complement inhibition and a cholesteral vaccine. None of these programs are even close to PhaseIII trial, where 80 % of new drugs fail. The emphasis on these new treatments are a smokescreen for the failures of the past. Tcell has very limited capital to expand trials and the merger which diluted all original Tcell shareholders has done nothing but that, dilute what equity longterm shareholders have paid for previously. I think we were all head faked by Una Ryan's delusions of grandeur for the company.Time will tell who is right. IMO